These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 17046050

  • 1. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
    Nakamura T, Uchiyama S, Yamazaki M, Iwata M.
    Thromb Res; 2007; 119(4):511-6. PubMed ID: 17046050
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dipyridamole potentiates the inhibition of platelet aggregation by aspirin (in human platelet rich plasma and whole blood).
    Violi F, Praticò D, Iuliano L, Balsano F.
    J Lipid Mediat; 1991; 4(1):61-7. PubMed ID: 1909906
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.
    Satoh K, Fukasawa I, Kanemaru K, Yoda S, Kimura Y, Inoue O, Ohta M, Kinouchi H, Ozaki Y.
    Thromb Res; 2012 Oct; 130(4):616-21. PubMed ID: 22728022
    [Abstract] [Full Text] [Related]

  • 6. Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma.
    Nakamura T, Uchiyama S, Yamazaki M, Iwata M.
    Cerebrovasc Dis; 2002 Oct; 14(3-4):234-8. PubMed ID: 12403957
    [Abstract] [Full Text] [Related]

  • 7. Dipyridamole inhibits platelet aggregation in whole blood.
    Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M.
    Thromb Haemost; 1983 Dec 30; 50(4):852-6. PubMed ID: 6665766
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.
    Agarwal KC, Zielinski BA, Maitra RS.
    Thromb Haemost; 1989 Feb 28; 61(1):106-10. PubMed ID: 2749584
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.
    Gresele P, Arnout J, Deckmyn H, Vermylen J.
    Thromb Haemost; 1986 Feb 28; 55(1):12-8. PubMed ID: 3704998
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood.
    Kariyazono H, Nakamura K, Arima J, Ayukawa O, Onimaru S, Masuda H, Iguro Y, Majima HJ, Sakata R, Yamada K.
    Blood Coagul Fibrinolysis; 2004 Mar 28; 15(2):157-67. PubMed ID: 15091003
    [Abstract] [Full Text] [Related]

  • 13. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
    Nomura S, Inami N, Iwasaka T, Liu Y.
    Platelets; 2004 May 28; 15(3):167-72. PubMed ID: 15203718
    [Abstract] [Full Text] [Related]

  • 14. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents.
    Yamazaki M, Uchiyama S, Xiong Y, Nakano T, Nakamura T, Iwata M.
    Thromb Res; 2005 May 28; 115(3):211-8. PubMed ID: 15617744
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
    Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, Kimura Y, Ikeda Y, Shiku H, Nishikawa M.
    Life Sci; 1997 May 28; 61(25):PL 383-9. PubMed ID: 9416770
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
    Woo SK, Kang WK, Kwon KI.
    Clin Pharmacol Ther; 2002 Apr 28; 71(4):246-52. PubMed ID: 11956507
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood.
    Stafford NP, Pink AE, White AE, Glenn JR, Heptinstall S.
    Arterioscler Thromb Vasc Biol; 2003 Oct 01; 23(10):1928-33. PubMed ID: 12893689
    [Abstract] [Full Text] [Related]

  • 18. Dipyridamole potentiates platelet inhibition by nitric oxide.
    Bult H, Fret HR, Jordaens FH, Herman AG.
    Thromb Haemost; 1991 Sep 02; 66(3):343-9. PubMed ID: 1746006
    [Abstract] [Full Text] [Related]

  • 19. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
    Dawicki DD, Agarwal KC, Parks RE.
    Thromb Res; 1986 Jul 15; 43(2):161-75. PubMed ID: 3016942
    [Abstract] [Full Text] [Related]

  • 20. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
    Bullough DA, Zhang C, Montag A, Mullane KM, Young MA.
    J Clin Invest; 1994 Oct 15; 94(4):1524-32. PubMed ID: 7929829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.